Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2

J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e649-e651. doi: 10.1111/jdv.17480. Epub 2021 Jul 12.

Authors

F Solimani¹, Y Mansour¹, D Didona², A Dilling¹, K Ghoreschi¹, K Meier¹

Affiliations

¹ Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
² Department of Dermatology and Allergology, Philipps University, Marburg, Germany.

No abstract available

Publication types

Letter

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Humans
Pemphigus*
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines
BNT162 Vaccine

Grants and funding

FOR 2497/TP02/Deutsche Forschungsgemeinschaft